Nanoism: The Emergence of a New Medical Field in Preventive Medicine

Nanoism™, founded by Tess Fries in 2025, is introduced in this white paper as a new medical field in preventive medicine. Nanoism unifies previously separate scientific domains—nanoscale engineering, artificial intelligence, autonomy, and preventive medicine—into a coherent discipline designed to shift medicine from reactive treatment to proactive protection.

As its first realization, the paper presents Elixira—a patent-pending, AI-guided nanomedicine platform created by inventor and founder Tess Fries in 2025, designed for autonomous, lifelong cancer prevention across all cancer types. Elixira exemplifies Nanoism’s defining pillars: nanoscale intervention, AI-guided autonomy, prevention-first orientation, and self-sufficient symbiosis with the human body.

Formally introduced under the title “Nanoism: The Emergence of a New Medical Field in Preventive Medicine,” this publication establishes a permanent and citable public record defining the scope, principles, and feasibility of Nanoism as a distinct medical discipline.

This public disclosure establishes priority as prior art for the concepts presented, while deliberately omitting enabling details to protect sensitive intellectual property. Authored and published by Tess Fries, it constitutes an official disclosure affirming ownership and authorship, and marks the emergence of Nanoism as a distinct field shaping the future of medicine.